GlassScriptPhysician profile
Mandie Michelle Brown
NPI 1942808506
$2,048.58
in general payments reported to CMS, 2019-2025
33 companies · $863 in 2025
The $863 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $324 · 2023: $294 · 2024: $567 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.97 |
| Education | $106.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $224.91 | 2024-2025 | Calquence, Enhertu, Lynparza |
| Abbvie INC. | $192.91 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $166.25 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $139.71 | 2022-2025 | Opdualag |
| Janssen Biotech, INC. | $123.66 | 2025 | Tecvayli, Darzalex, Balversa |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $93.49 | 2023 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $91.33 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $87.73 | 2024-2025 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $77.75 | 2022-2023 | Imbruvica, Epkinly |
| Iovance Biotherapeutics, INC. | $63.77 | 2025 | Amtagvi |
| Beigene USA, INC. | $54.03 | 2023-2024 | Brukinsa |
| Lilly USA, LLC | $50.24 | 2024-2025 | Jaypirca, Verzenio |
| Mirati Therapeutics, INC. | $47.49 | 2023-2024 | Krazati |
| Cti Biopharma Corp. | $45.49 | 2022-2023 | Vonjo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.49 | 2024-2025 | |
| Genzyme Corporation | $38.19 | 2024 | |
| Beone Medicines USA, INC. | $34.29 | 2025 | Tevimbra |
| Eisai INC. | $33.36 | 2022-2024 | |
| Coherus Oncology, INC. | $33.31 | 2024 | |
| Blueprint Medicines Corporation | $32.47 | 2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.26 | 2024 | Gilotrif |
| Incyte Corporation | $30.37 | 2022-2024 | Jakafi |
| Genmab U.S., INC. | $30.20 | 2025 | Epkinly |
| Seagen INC. | $27.88 | 2023 | Tukysa |
| Glaxosmithkline, LLC. | $24.78 | 2025 | Ojjaara |
| Astellas Pharma US INC | $21.49 | 2025 | Vyloy |
| Celgene Corporation | $19.80 | 2024 | Reblozyl |
| Geron Corporation | $19.11 | 2025 | Rytelo |
| Genentech USA, INC. | $18.95 | 2025 | Polivy |
| Agios Pharmaceuticals, INC. | $18.23 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2025 | Rexulti |
| Stemline Therapeutics INC. | $16.64 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.